Established and new treatment roadmaps for pleural mesothelioma: opinions of the Turkish Collaborative Group

Basit Öğe Kaydı
dc.authoridKAYI CANGIR, AYTEN/0000-0002-2052-1642;
dc.authorwosidKAYI CANGIR, AYTEN/ABS-8995-2022
dc.authorwosidSendur, Mehmet Ali Nahit/H-7555-2014
dc.contributor.authorKaplan, Muhammet Ali
dc.contributor.authorSendur, Mehmet Ali Nahit
dc.contributor.authorCangir, Ayten Kayi
dc.contributor.authorFirat, Pinar
dc.contributor.authorGoker, Erdem
dc.contributor.authorKilickap, Saadettin
dc.contributor.authorOyan, Basak
dc.date.accessioned2024-05-19T14:39:26Z
dc.date.available2024-05-19T14:39:26Z
dc.date.issued2023
dc.departmentİstinye Üniversitesien_US
dc.description.abstractPleural mesothelioma (PM) is a cancer of the pleural surface, which is aggressive and may be rapidly fa-tal. PM is a rare cancer worldwide, but is a relatively common disease in Turkey. Asbestos exposure is the main risk factor and the most common underlying cause of the disease. There have been significant im-provements in diagnoses and treatments of many malignancies; however, there are still therapeutic chal-lenges in PM. In this review, we aimed to increase the awareness of health care professionals, oncolo-gists, and pulmonologists by underlining the unmet needs of patients with PM and by emphasizing the need for a multidisciplinary treatment and management of PM. After reviewing the general information about PM, we further discuss the treatment options for patients with PM using immunotherapy and offer evidence for improvements in the clinical outcomes of these patients because of these newer treatment modalities.(c) 2023 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )en_US
dc.description.sponsorshipBristol Myers Squibb, Istanbul, Turkeyen_US
dc.description.sponsorshipThe authors thank Safak Duelger (BSc) from Omega CRO, Ankara, Turkey for professional medical writing and assistance, with funding from Bristol Myers Squibb, Istanbul, Turkey.en_US
dc.identifier.doi10.1016/j.currproblcancer.2023.101017
dc.identifier.issn0147-0272
dc.identifier.issn1535-6345
dc.identifier.issue6en_US
dc.identifier.pmid37845104en_US
dc.identifier.scopus2-s2.0-85173875640en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org10.1016/j.currproblcancer.2023.101017
dc.identifier.urihttps://hdl.handle.net/20.500.12713/4779
dc.identifier.volume47en_US
dc.identifier.wosWOS:001125100500001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherMosby-Elsevieren_US
dc.relation.ispartofCurrent Problems In Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240519_kaen_US
dc.subjectBiomarkeren_US
dc.subjectCanceren_US
dc.subjectChemotherapyen_US
dc.subjectImmune Checkpoint Inhibitoren_US
dc.subjectImmunotherapyen_US
dc.subjectPleural Mesotheliomaen_US
dc.titleEstablished and new treatment roadmaps for pleural mesothelioma: opinions of the Turkish Collaborative Groupen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu